Copy to clipboard 
Smith+Nephew Segment Performance 2016 – 2025
Smith+Nephew finished 2025 with its strongest orthopedic performance in years. Both knees and hips were slightly below market but still very respectable. Trauma and Extremities grew nearly 7%, while Sports Medicine was able to grow more than 6% in the face of looming volume-based procurement tenders in China on sports medicine enabling technology products.
In this chart of the month, we take a look at the 10-year growth trends for each of the company’s major orthopedic segments. The biggest trends that jump out to us are the continued strength of sports medicine and the company’s opportunity to turn around its hip franchise.
The company’s sports medicine business has a 10-year CAGR of 4%. That is a little bit below the market growth rate, but during that time, the company had to overhaul parts of its product offering and contend with massive upheavals in the Chinese market.
In hips, the company’s CAGR over the last decade is 0.7%. Smith+Nephew’s Trauma and Extremities business, no world-beater itself, surpassed hips in terms of total revenue for the first time in 2025. However, recent quarters have given the company reason to believe things are changing.
Hips have averaged over 6% growth for four consecutive quarters, driven by uptake of the CATALYSTEM line in competitive accounts.
“U.S. hips we now know is leading the market, which 3 years ago, we could never imagine that we would be doing that. So what that reflects is fundamental improvements in how we operate the business, commercial execution, supply and a product portfolio that’s lined up with kind of where the market is today,” said Smith+Nephew CEO Deepak Nath.
Smith+Nephew Segment Performance 2016 - 2025
Smith+Nephew finished 2025 with its strongest orthopedic performance in years. Both knees and hips were slightly below market but still very respectable. Trauma and Extremities grew nearly 7%, while Sports Medicine was able to grow more than 6% in the face of looming volume-based procurement...
Smith+Nephew Segment Performance 2016 – 2025
Smith+Nephew finished 2025 with its strongest orthopedic performance in years. Both knees and hips were slightly below market but still very respectable. Trauma and Extremities grew nearly 7%, while Sports Medicine was able to grow more than 6% in the face of looming volume-based procurement tenders in China on sports medicine enabling technology products.
In this chart of the month, we take a look at the 10-year growth trends for each of the company’s major orthopedic segments. The biggest trends that jump out to us are the continued strength of sports medicine and the company’s opportunity to turn around its hip franchise.
The company’s sports medicine business has a 10-year CAGR of 4%. That is a little bit below the market growth rate, but during that time, the company had to overhaul parts of its product offering and contend with massive upheavals in the Chinese market.
In hips, the company’s CAGR over the last decade is 0.7%. Smith+Nephew’s Trauma and Extremities business, no world-beater itself, surpassed hips in terms of total revenue for the first time in 2025. However, recent quarters have given the company reason to believe things are changing.
Hips have averaged over 6% growth for four consecutive quarters, driven by uptake of the CATALYSTEM line in competitive accounts.
“U.S. hips we now know is leading the market, which 3 years ago, we could never imagine that we would be doing that. So what that reflects is fundamental improvements in how we operate the business, commercial execution, supply and a product portfolio that’s lined up with kind of where the market is today,” said Smith+Nephew CEO Deepak Nath.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
